Anaphylaxis treatment: Current barriers to adrenaline auto-injector use

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 8, 2014, Pages 983-991

  Song, T T ^a   Worm, M ^b   Lieberman, P ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

adrenaline; anaphylaxis; auto injector; food allergy; regulatory issues

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT;

ANAPHYLAXIS; AWARENESS; DRUG BIOAVAILABILITY; DRUG EFFECT; EMERGENCY CARE; EUROPE; HEALTH PRACTITIONER; HUMAN; MUSCLE TISSUE; PATIENT RISK; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED STATES; DISEASE MANAGEMENT; DRUG SELF ADMINISTRATION; EMERGENCY HEALTH SERVICE; INTRAMUSCULAR DRUG ADMINISTRATION; RISK FACTOR; TREATMENT OUTCOME;

ADRENERGIC ALPHA-AGONISTS; ANAPHYLAXIS; DISEASE MANAGEMENT; EMERGENCY MEDICAL SERVICES; EPINEPHRINE; HUMANS; INJECTIONS, INTRAMUSCULAR; PREVALENCE; RISK FACTORS; SELF ADMINISTRATION; TREATMENT OUTCOME;

EID: 84904042506     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12387     Document Type: Review

References (74)

1. Cohen SG, Zelaya-Quesada M,. Portier, Richet, and the discovery of anaphylaxis: a centennial. J Allergy Clin Immunol 2002; 110: 331-336.
2. Atkins D, Bock SA,. Fatal anaphylaxis to foods: epidemiology, recognition, and prevention. Curr Allergy Asthma Rep 2009; 9: 179-185.
3. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117: 391-397.
4. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-836.
5. Simons FE, Ardusso LR, Bilo MB, El-Gamal YM, Ledford DK, Ring J, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 2011a; 4: 13-37.
6. Ring J, Behrendt H,. Anaphylaxis and anaphylactoid reactions. Classification and pathophysiology. Clin Rev Allergy Immunol 1999; 17: 387-399.
7. Moneret-Vautrin DA, Morisset M, Flabbee J, Beaudouin E, Kanny G,. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy 2005; 60: 443-451.
8. Liberman DB, Teach SJ,. Management of anaphylaxis in children. Pediatr Emerg Care 2008; 24: 861-866.
9. Worm M, Edenharter G, Rueff F, Scherer K, Pfohler C, Mahler V, et al. Symptom profile and risk factors of anaphylaxis in Central Europe. Allergy 2012; 67: 691-698.
10. Fisher M,. Treatment of acute anaphylaxis. BMJ 1995; 311: 731-733.
11. McLean-Tooke AP, Bethune CA, Fay AC, Spickett GP,. Adrenaline in the treatment of anaphylaxis: what is the evidence? BMJ 2003; 327: 1332-1335.
12. Ross MP, Ferguson M, Street D, Klontz K, Schroeder T, Luccioli S,. Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System. J Allergy Clin Immunol 2008; 121: 166-171.
13. Lieberman P, Camargo CA Jr, Bohlke K, Jick H, Miller RL, Sheikh A, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 2006; 97: 596-602.
14. Sheikh A, Hippisley-Cox J, Newton J, Fenty J,. Trends in national incidence, lifetime prevalence and adrenaline prescribing for anaphylaxis in England. J R Soc Med 2008; 101: 139-143.
15. Gaeta TJ, Clark S, Pelletier AJ, Camargo CA,. National study of US emergency department visits for acute allergic reactions, 1993 to 2004. Ann Allergy Asthma Immunol 2007; 98: 360-365.
16. Lin RY, Anderson AS, Shah SN, Nurruzzaman F,. Increasing anaphylaxis hospitalizations in the first 2 decades of life: New York State, 1990-2006. Ann Allergy Asthma Immunol 2008; 101: 387-393.
17. Poulos LM, Waters AM, Correll PK, Loblay RH, Marks GB,. Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005. J Allergy Clin Immunol 2007; 120: 878-884.
18. Gupta R, Sheikh A, Strachan DP, Anderson HR,. Time trends in allergic disorders in the UK. Thorax 2007; 62: 91-96.
19. Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126: 477-480.
20. Sampson HA, Munoz-Furlong A, Bock SA, Schmitt C, Bass R, Chowdhury BA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115: 584-591.
21. Pumphrey R,. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004; 4: 285-290.
22. Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 6 (Suppl 6): S1-S58.
23. Pumphrey RS,. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30: 1144-1150.
24. Sicherer SH, Sampson HA, Bock SA, Munoz-Furlong A,. Underrepresentation of the risk and incidence of anaphylaxis to foods. Arch Intern Med 2001; 161: 2046-2047.
25. Simons FE,. Anaphylaxis. J Allergy Clin Immunol 2010; 125 (2 Suppl 2): S161-S181.
26. Pumphrey RS, Gowland MH,. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119: 1018-1019.
27. Burks AW, Tang M, Sicherer S, Muraro A, Eigenmann PA, Ebisawa M, et al. ICON: food allergy. J Allergy Clin Immunol 2012; 129: 906-920.
28. Austen KF,. Systemic anaphylaxis in the human being. N Engl J Med 1974; 291: 661-664.
29. Warren JB, McCusker M, Fuller RW,. Systemic adrenaline attenuates skin response to antigen and histamine. Clin Allergy 1988; 18: 197-199.
30. Westfall C, Westfall D,. Adrenergic agonists and antagonists. In:, Bruton L, Chabner B, Knollmann B, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edn. New York: McGraw-Hill, 2012: 282-287. Chapter 12.
31. Barnard JH,. Studies of 400 Hymenoptera sting deaths in the United States. J Allergy Clin Immunol 1973; 52: 259-264.
32. Sampson HA,. Anaphylaxis and emergency treatment. Pediatrics 2003; 111: 1601-1608.
33. Simons FE, Ardusso LR, Bilo MB, El-Gamal YM, Ledford DK, Ring J, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011b; 127: 587-593.
34. Sicherer SH, Simons FE,. Quandaries in prescribing an emergency action plan and self-injectable epinephrine for first-aid management of anaphylaxis in the community. J Allergy Clin Immunol 2005; 115: 575-583.
35. Davis J,. Self-injectable epinephrine for allergic emergencies. J Emerg Med 2009; 37: 57-62.
36. Frew AJ,. What are the 'ideal' features of an adrenaline (epinephrine) auto-injector in the treatment of anaphylaxis? Allergy 2011; 66: 15-24.
37. Schwirtz A, Seeger H,. Comparison of the robustness and functionality of three adrenaline auto-injectors. J Asthma Allergy 2012; 5: 39-49.
38. Simons FE,. Lack of worldwide availability of epinephrine autoinjectors for outpatients at risk of anaphylaxis. Ann Allergy Asthma Immunol 2005; 94: 534-538.
39. Campbell RL, Luke A, Weaver AL, St Sauver JL, Bergstralh EJ, Li JT, et al. Prescriptions for self-injectable epinephrine and follow-up referral in emergency department patients presenting with anaphylaxis. Ann Allergy Asthma Immunol 2008; 101: 631-636.
40. Mehl A, Wahn U, Niggemann B,. Anaphylactic reactions in children- A questionnaire-based survey in Germany. Allergy 2005; 60: 1440-1445.
41. Grabenhenrich L, Hompes S, Gough H, Rueff F, Scherer K, Pfohler C, et al. Implementation of anaphylaxis management guidelines: a register-based study. PLoS ONE 2012; 7: e35778.
42. Jones DH, Romero FA, Casale TB,. Time-dependent inhibition of histamine-induced cutaneous responses by oral and intramuscular diphenhydramine and oral fexofenadine. Ann Allergy Asthma Immunol 2008; 100: 452-456.
43. Atkinson TP, Kaliner MA,. Anaphylaxis. Med Clin North Am 1992; 76: 841-855.
44. Sreerekha, Rai R, Shanmuga SV, Karthick, Prabhu S, Srinivas CR, et al. Study of histamine wheal suppression by dexamethasone with and without iontophoresis. Indian J Dermatol Venereol Leprol 2006; 72: 283-285.
45. Brown AF,. Therapeutic controversies in the management of acute anaphylaxis. J Accid Emerg Med 1998; 15: 89-95.
46. Bochner BS, Lichtenstein LM,. Anaphylaxis. N Engl J Med 1991; 324: 1785-1790.
47. Brown AF,. Anaphylactic shock: mechanisms and treatment. J Accid Emerg Med 1995; 12: 89-100.
48. Kastner M, Harada L, Waserman S,. Gaps in anaphylaxis management at the level of physicians, patients, and the community: a systematic review of the literature. Allergy 2010; 65: 435-444.
49. Pumphrey RS, Roberts IS,. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 2000; 53: 273-276.
50. Mullins RJ,. Anaphylaxis: risk factors for recurrence. Clin Exp Allergy 2003; 33: 1033-1040.
51. Pumphrey RS, Stanworth SJ,. The clinical spectrum of anaphylaxis in north-west England. Clin Exp Allergy 1996; 26: 1364-1370.
52. Sampson HA,. Fatal food-induced anaphylaxis. Allergy 1998; 53 (Suppl 46): 125-130.
53. Sampson HA, Mendelson L, Rosen JP,. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327: 380-384.
54. Hourihane JO, Grimshaw KE, Lewis SA, Briggs RA, Trewin JB, King RM, et al. Does severity of low-dose, double-blind, placebo-controlled food challenges reflect severity of allergic reactions to peanut in the community? Clin Exp Allergy 2005; 35: 1227-1233.
55. Muraro A, Roberts G, Clark A, Eigenmann PA, Halken S, Lack G, et al. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy 2007; 62: 857-871.
56. EAACI. Food Allergy & Anaphylaxis Public Declaration. Zurich: EAACI, 2013.
57. Muraro A, Clark A, Beyer K, Borrego LM, Borres M, Lodrup Carlsen KC, et al. The management of the allergic child at school: EAACI/GA2LEN Task Force on the allergic child at school. Allergy 2010; 65: 681-689.
58. Eigenmann PA, Zamora SA,. An internet-based survey on the circumstances of food-induced reactions following the diagnosis of IgE-mediated food allergy. Allergy 2002; 57: 449-453.
59. McIntyre CL, Sheetz AH, Carroll CR, Young MC,. Administration of epinephrine for life-threatening allergic reactions in school settings. Pediatrics 2005; 116: 1134-1140.
60. Bohlke K, Davis RL, DeStefano F, Marcy SM, Braun MM, Thompson RS,. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. J Allergy Clin Immunol 2004; 113: 536-542.
61. Rankin KE, Sheikh A,. Serious shortcomings in the management of children with anaphylaxis in Scottish schools. PLoS Med 2006; 3: e326.
62. Fitzharris P, Empson M, Ameratunga R, Sinclair J, Crump V, Steele R, et al. Anaphylaxis management: the essential role of adrenaline (epinephrine) auto-injectors. Should PHARMAC fund them in New Zealand? N Z Med J 2006; 119: U1965.
63. Goldberg A, Confino-Cohen R,. Insect sting-inflicted systemic reactions: attitudes of patients with insect venom allergy regarding after-sting behavior and proper administration of epinephrine. J Allergy Clin Immunol 2000; 106: 1184-1189.
64. Gold MS, Sainsbury R,. First aid anaphylaxis management in children who were prescribed an epinephrine autoinjector device (EpiPen). J Allergy Clin Immunol 2000; 106: 171-176.
65. Ben-Shoshan M, Kagan R, Primeau MN, Alizadehfar R, Verreault N, Yu JW, et al. Availability of the epinephrine autoinjector at school in children with peanut allergy. Ann Allergy Asthma Immunol 2008; 100: 570-575.
66. Marrs T, Lack G,. Why do few food-allergic adolescents treat anaphylaxis with adrenaline? Reviewing a pressing issue. Pediatr Allergy Immunol 2013; 24: 222-229.
67. Simons FE, Roberts JR, Gu X, Simons KJ,. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998; 101: 33-37.
68. Simons FE, Gu X, Silver NA, Simons KJ,. EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis. J Allergy Clin Immunol 2002; 109: 171-175.
69. Simons FE, Gu X, Simons KJ,. Outdated EpiPen and EpiPen Jr autoinjectors: past their prime? J Allergy Clin Immunol 2000; 105: 1025-1030.
70. Sclar DA,. Bioequivalence evaluation of epinephrine autoinjectors with attention to rapid delivery. Ther Clin Risk Manag 2013; 9: 149-151.
71. Edwards ES, Gunn R, Simons ER, Carr K, Chinchilli VM, Painter G, et al. Bioavailability of epinephrine from Auvi-Q compared with EpiPen. Ann Allergy Asthma Immunol 2013; 111: 132-137.
72. Simons FE,. Benefits and risks of inhaled glucocorticoids in children with persistent asthma. J Allergy Clin Immunol 1998; 102: S77-S84.
73. Baker TW, Webber CM, Stolfi A, Gonzalez-Reyes E,. The TEN study: time epinephrine needs to reach muscle. Ann Allergy Asthma Immunol 2011; 107: 235-238.
74. Song TT, Merrill NL, Cole JW,. Delivery depth of epinephrine by auto-injector into the subcutaneous tissue of pig. Ann Allergy Asthma Immunol 2013; 111: 143-145.